Podcasts about spectrum news ny1

In office less than two months, President Donald Trump is sending economic shockwaves across the world — including New York City. From cutting the federal workforce to launching massive tariffs, Trump's fiscal moves are already having an impact on Wall Street and the rest of the five boroughs. Greg David, an economics reporter from the news outlet The City, has been detailing how Trump's measures could affect New York City residents. David joined NY1's Errol Louis to discuss the vulnerabilities of various federal aid programs like Medicaid and food stamps, the potential effects of the stock market's decline, what tariffs could mean for local businesses and the broader economic impact for the city's post-pandemic recovery. They also examined the lack of clarity on economic policies among New York mayoral candidates. ***Spectrum News NY1 and Roosevelt House will be co-hosting a special panel discussion on the political career and legacy of New York City Mayor John Lindsay. Inspired by the NY1 three-part limited audio series covering Lindsay's political career, the conversation will be held at Roosevelt House on March 13 at 6 p.m. It will be moderated Errol Louis and feature a panel of Lindsay administration alumni and journalists who will discuss Lindsay's eight years in office from 1966 to 1973 — one of the most chaotic and transformative times in New York's recent history. It will explore his accomplishments as mayor, as well as the staggering number of challenges he faced during his two terms. Attendees will need to RSVP to the event, which is free, through Roosevelt House, here: https://ny1.com/nyc/all-boroughs/you-decide-with-errol-louis/2025/02/06/john-lindsay-new-york-city-mayor-panel-you-decide-crisis-and-accomplishment  Join the conversation, weigh in on Twitter using the hashtag #NY1YouDecide or give us a call at 212-379-3440 and leave a message. Or send an email to YourStoryNY1@charter.com.

After much anticipation, former New York Gov. Andrew Cuomo officially entered the race for New York City mayor, joining a crowded Democratic primary field. Cuomo resigned in 2021 amid 11 allegations of sexual harassment, though Cuomo has denied wrongdoing. NY1's Errol Louis spoke about Cuomo's legacy and his future, with Christopher Robbins, an editor and co-founder of the news outlet Hell Gate. They also talked about recent polling that shows Mayor Eric Adams' job approval rating dipping to an all-time low. And they discussed the reasons why Robbins started Hell Gate and what he sees in the future for the news outlet. ***Spectrum News NY1 and Roosevelt House will be co-hosting a special panel discussion on the political career and legacy of New York City Mayor John Lindsay. Inspired by the NY1 three-part limited audio series covering Lindsay's political career, the conversation will be held at Roosevelt House on March 13 at 6 p.m. It will be moderated Errol Louis and feature a panel of Lindsay administration alumni and journalists who will discuss Lindsay's eight years in office from 1966 to 1973 — one of the most chaotic and transformative times in New York's recent history. It will explore his accomplishments as mayor, as well as the staggering number of challenges he faced during his two terms. Anyone who wishes to attend the event will need to RSVP. To learn more visit: ny1.com.

The five months since Mayor Eric Adams was indicted have consisted of an extraordinary sequence of events that has found the mayor bruised but emboldened, still firmly in office, and about to launch a campaign for re-election. Katie Honan, a reporter for The CITY and co-host of the FAQ NYC podcast, has been closely following the mayor through these many twists and turns. Honan joined NY1's Errol Louis to discuss several issues surrounding Adams, including his legal troubles, loss of security clearance, and the recent resignations of four deputy mayors on the same day. They also touched on the strategies of other mayoral candidates as they prepare for the June primary, including the “will he or won't he” role of Andrew Cuomo in the race.  ***Spectrum News NY1 and Roosevelt House will be co-hosting a special panel discussion on the political career and legacy of New York City Mayor John Lindsay. Inspired by the NY1 three-part limited audio series covering Lindsay's political career, the conversation will be held at Roosevelt House on March 13 at 6 p.m. It will be moderated Errol Louis and feature a panel of Lindsay administration alumni and journalists who will discuss Lindsay's eight years in office from 1966 to 1973 — one of the most chaotic and transformative times in New York's recent history. It will explore his accomplishments as mayor, as well as the staggering number of challenges he faced during his two terms. Attendees will need to RSVP to the event, which is free, through Roosevelt House, here: https://ny1.com/nyc/all-boroughs/you-decide-with-errol-louis/2025/02/06/john-lindsay-new-york-city-mayor-panel-you-decide-crisis-and-accomplishment

In 1969, John Lindsay's first term as mayor of New York City was coming to a close. After a series of labor disputes and a botched snowstorm recovery that shut down the city, his poll numbers were at an all-time low. Somehow, even after losing the Republican primary, he found a road to reelection.  In the final installment of this three-part podcast series by Spectrum News NY1, Errol Louis explores Lindsay's unlikely path to victory, his second term as mayor and his ill-advised presidential run. The episode also looks at Lindsay's enduring legacy and his innovative yet controversial ideas for urban development. Join the conversation, weigh in on Twitter using the hashtag #NY1YouDecide or give us a call at 212-379-3440 and leave a message. Or send an email to YourStoryNY1@charter.com.

From the moment he became mayor of New York City in 1966, John Lindsay faced a city in turmoil when subway workers walked off the job and went on strike for 12 days. In many ways, it never got any easier for Lindsay, who ran the city in a time of national upheaval.  In part two of a three-part podcast series by Spectrum News NY1, Errol Louis explores John Lindsay's chaotic first term, in which the mayor tried to continue pushing forward, combating a string of labor disputes while attempting to create a more livable city. Join the conversation, weigh in on Twitter using the hashtag #NY1YouDecide, give us a call at 212-379-3440 and leave a message, or send an email to YourStoryNY1@charter.com.

In 1965, New York City was teetering on the edge of an uncertain future, but a Republican congressman from the Upper East Side was determined to save it. Fighting traditional power brokers and machine politicians, John Lindsay improbably was elected mayor that year; his eight years in office became one of the most tumultuous and transformative times in New York's recent history. In part one of a three-part podcast series by Spectrum News NY1, Errol Louis explores John Lindsay's turbulent New York, focusing on his early years in Congress and building up to being elected mayor in a dramatic three-way race in November of 1965. Join the conversation, weigh in on Twitter using the hashtag #NY1YouDecide or give us a call at 212-379-3440 and leave a message. Or send an email to YourStoryNY1@charter.com.

Juan Manuel Benitez, former longtime reporter and host at Spectrum News NY1, now professor at the Columbia Journalism School, recaps the second night of the Democratic National Convention, plus talks about how the Harris campaign is reaching out to Latino voters. Plus: John Avlon, veteran journalist now the Democratic candidate for congress in New York's 1st district on Long Island, joins Brian briefly to talk about his race against one-term Republican incumbent Nick LaLota.

The Democratic National Convention continues, with participants reporting a joyful energy and an excitement about their party. On Today's Show:Juan Manuel Benitez, former longtime reporter and host at Spectrum News NY1 and NY1 Noticias, now professor at the Columbia Journalism School, recaps the second night of the Democratic National Convention, plus talks about how the Harris campaign is reaching out to Latino voters.

Harry Siegel, editor at The City, "FAQ NYC" podcast co-host, and Daily News columnist, and Dean Meminger, reporter and anchor for Spectrum News/NY1 covering criminal justice, talk about the city and state responses to crime and mental illness on the subways.

In just a few months, congestion pricing will come to New York City. Most drivers will have to pay a $15 fee to enter Manhattan below Central Park. The Metropolitan Transportation Authority hopes congestion pricing will lead to reduced traffic, less pollution and more money for roads and public transportation infrastructure. But the program took nearly two decades to come to fruition, and there are a lot of details still being worked out before it is implemented. Host Pat Kiernan speaks with his Spectrum News NY1 colleagues about what congestion pricing means for New Yorkers.

For more than 30 years, Annika Pergament has been bringing her tenacity and sophisticated storytelling to the journalism field. Now, she embarks on a new role as the 4 p.m. anchor on Spectrum News NY1. Pat Kiernan, a longtime colleague and friend, sits down with his co-worker to discuss what brought her into journalism, what stories she likes to cover and how NY1 has shaped her life outside of the studio.

Last week, the yearlong lookback window allowing adult victims of sexual assault to file lawsuits against their perpetrators closed. Bernadette Hogan, statehouse reporter at Spectrum News NY1, discusses the end of the Adult Survivors Act lookback window, the flurry of cases against high profile characters that came in, as well as efforts to potentially reinstate the law, providing another opportunity for victims to seek justice.  

Eric Feldman, General Assignment Reporter, Spectrum News NY1 twitter.com/EricSFeldman Tom Drew, Vice President Regional Sales Manager at Citizens Bank https://www.citizensbank.com/homepage.aspxSee omnystudio.com/listener for privacy information.

This week, Keechant Sewell suddenly announced her resignation from leading the nation's largest police department. The decision comes only one-and-a-half years into her tenure and at a time when all major crime categories were trending down. Sewell became New York City's first woman police commissioner when Mayor Eric Adams appointed her to the position in December 2021. NY1's Juan Manuel Benítez, Courtney Gross and Emily Ngo weighed in on the commissioner's decision, and discussed the unusually high rate of turnover in the Adams administration.    After that, City Council primaries are less than two weeks away and the “Off Topic/On Politics” team highlighted several of the more competitive races, including one in District 1 in Chinatown and Lower Manhattan. One of the key issues in that race is how the closing of the city's jails on Rikers Island could affect the district. They also looked at District 9 in Harlem, where a serious concern is affordable housing. Finally, the team briefly explained ranked-choice voting.   Spectrum News NY1 hosted two City Council primary debates for District 1 and District 9. You can watch both of the debates on NY1.com.   Leave a message: 212-379-3440 Email: yourstoryny1@charter.com   Further reading:  Mayor offers praise, but no explanation for police commissioner's sudden exit Mayor Eric Adams endorses Inez Dickens for Harlem seat

Three Democratic candidates for the 9th City Council District in Manhattan squared off in a primary debate, hosted by Errol Louis on Spectrum News/NY1. The district includes much of Harlem, and the seat is currently held by Kristin Richardson Jordan, who announced last month that she would not be running for re-election. While her name will still appear on the ballot, there are three candidates vying for the position: Yusef Salaam, Inez Dickens and Al Taylor. When it came to housing, the candidates discussed how they want to utilize a controversial site on 145th Street in Harlem. They also talked about the legal cannabis market, the resignation of NYPD Commissioner Keechant Sewell and migrants arriving in the city and public safety in Harlem.  Join the conversation, weigh in on Twitter using the hashtag #NY1YouDecide or give us a call at 212-379-3440 and leave a message. Or send an email to YourStoryNY1@charter.com

Jane Krakowski shares stories from her performances in ‘30 Rock', ‘Nine' and ‘Ally McBeal' in this in this career spanning discussion moderated by Frank DiLella, Spectrum News NY1. This interview is part of the SAG-AFTRA Foundation Conversations series, an essential resource for actors, filmmakers and students of discussions with performers, exploring the process and profession of acting. The views expressed in the presentation materials and films, and by the guests and moderators are solely those of the organization and/or individual providing them and do not reflect the opinions of the SAG-AFTRA Foundation, its staff or Board of Directors. Watch Past Q&A's: https://www.youtube.com/c/SAGAFTRAFoundation/videos Follow the SAG-AFTRA Foundation on social media: Instagram: https://www.instagram.com/sagaftraFOUND/ Facebook: https://www.facebook.com/sagaftraFOUNDATION Twitter: https://twitter.com/sagaftraFOUND` The SAG-AFTRA Foundation is a 501(c)(3) nonprofit organization dedicated to providing the most comprehensive, educational and state-of-the-art resources to SAG-AFTRA members. The Foundation believes that the contributions made to our culture by performing artists are not only valuable, but essential. The SAG-AFTRA Foundation relies entirely on donations to provide emergency assistance and free educational programs to SAG-AFTRA artists. This conversation is made possible thanks to the generosity of our supporters. During the pandemic, the Foundation has given over $7 million in disaster relief to more than 7,500 performers. If you are a SAG-AFTRA artist and need help, please ask. And, if you can help, please give at: https://sagaftra.foundation/donate. All donations are tax-deductible.

On today's Episode Shanta speaks with an internal medicine physician and medical billing expert.With more than 20 years experience in primary care, psychiatric settings, and as a health insurance executive. When Dr. Virgie Bright Ellington became a cancer patient herself, she faced incredibly high medical bills. That's when she took her insider industry knowledge and put it to work. On this Episode Dr Virgie shares important information that can help you when it comes to your medical bills. She is the author of Crush Medical Debt. In Crush Medical Debt, she shares her secrets to shield individuals and families against America's number one cause of bankruptcy—medical debt. Dr Virgie has been featured in Voice America, Black Enterprise, Spectrum News NY1 and more. You will gain the knowledge and tools necessary to stand up to the medical providers. Find out what CPT means and why it is important to ask for this. *******************************Website: crushmedicaldebt.comThe book is also available on Amazon.*******************************Connect with the Host:AuthenticTalks2.com

Cindy interviews Spectrum News NY1 anchor Ruschell Boone on how she managed to triumphantly beat pancreatic cancer, which has a critically low survival rate. Learn more about your ad choices. Visit megaphone.fm/adchoices

Link from the show:* Connect with Matthew on Twitter* Connect with Ryan on Twitter* Subscribe to the newsletterAbout my guest:Dr. Matthew W. Johnson, Ph.D., is Professor of Psychiatry and Behavioral Sciences at Johns Hopkins. He is one of the world's most published scientists on the human effects of psychedelics, and has conducted seminal research in the behavioral economics of drug use, addiction, and risk behavior. Dr. Johnson earned his Ph.D. in experimental psychology at the University of Vermont in 2004.Working with psychedelics for 16 years, Dr. Johnson published psychedelic safety guidelines in 2008, helping to resurrect psychedelic research. As Principle Investigator he developed and published the first research on psychedelic treatment of tobacco addiction in 2014. Dr. Johnson and colleagues published the largest study of psilocybin in treating cancer distress in 2016. His 2018 psilocybin abuse liability review recommended placement in Schedule-IV upon potential medical approval. He is Principle Investigator on funded studies investigating psilocybin in the treatment of opioid dependence and PTSD. Beyond psilocybin, in 2011 Dr. Johnson published the first-ever blinded human research showing psychoactive effects of salvinorin A, the active constituent in Salvia divinorum. He also published in 2017 the first data indicating that MDMA pill testing services may reduce harm, specifically by reducing drug consumption of unknown or undesired adulterants.Dr. Johnson is recognized for his research in behavioral economics, behavioral pharmacology, and behavior analysis. He has conducted seminal and widely cited research applying behavioral economic principles such as delay discounting and demand analysis to decision making within addiction, drug consumption, and risk behavior. This includes research determining delay discounting to be a fundamental behavioral process underlying addiction across drug classes, using economic demand analysis to determine the roles of nicotine and nonpharmacological factors in the abuse liability tobacco and other nicotine products, and using delay discounting, probability discounting, and demand analysis to understand sexual risk including condom non-use in casual sex situations. He conducted the first research administering cocaine to humans in determining that cocaine increases sexual desire and affects sexual decision making. He has conducted similar research administering methamphetamine and alcohol, examining effects on sexual decision making. He has published studies on drugs across nearly all psychoactive classes, including studies of cocaine, methamphetamine, tobacco/nicotine, alcohol, opioids, cannabis, benzodiazepines, psilocybin, dextromethorphan, salvinorin A, GHB, caffeine, and cathinone analogs compounds (so-called “bath salts”).Dr. Johnson was 2019 President of the Psychopharmacology and Substance Abuse Division of the American Psychological Association, and is current President of the International Society for Research on Psychedelics, an organization he founded with colleagues. He has received continuous NIH funding as Principal Investigator since 2009. He has reviewed for >75 journals and has served as guest editor on two special issues on psychedelics. Dr. Johnson has reviewed grants for NIH, NSF, the US Military, and multiple governments outside of the US. He is a standing member of the Addictions Risks and Mechanisms (ARM) NIH study section. He has provided invited presentations in 13 nations.Dr. Johnson has been interviewed widely by media about psychedelics and other drugs. These have included interviews by the New York Times, the Washington Post, the Wall Street Journal, the Globe and Mail, the Daily Mail, USA Today, the Chicago Tribune, the San Francisco Chronicle, the Denver Post, the Baltimore Sun, CNN, CBS News, NBC News, the Atlantic, Newsweek, Vanity Fair, Marie Claire, Vogue, Whole Living, the Washingtonian, Scientific American, Nature, Vice, Insider, Inverse, Healthline, and Psychology Today. Dr. Johnson has appeared for interviews on numerous television and radio shows including 60 Minutes, CNN's Wolf Blitzer Situation Room, Fox Business News' Kennedy, the Dr. Oz Show, PBS' Retro Report, Labyrint (television show in the Netherlands), Spectrum News NY1, the BBC World Service, NPR's Morning Edition, NPR's Kojo Nnamdi Show, New Zealand Radio, and Newstalk Radio Ireland. Dr. Johnson's panel discussion with Tim Ferriss at the Milken Institute Global Conference was broadcast on the Tim Ferriss Podcast. Dr. Johnson and his research were featured in an episode of Breakthrough on the National Geographic Channel, produced by Ron Howard, and in Michael Pollan's best-selling book, How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and Transcendence. Get full access to Dispatches from the War Room at dispatchesfromthewarroom.substack.com/subscribe

The housing market in New York was upended during the pandemic. Record-high rents hit Manhattan, other boroughs saw spikes in apartment demands, and mortgage rates impacted buying. Whether you own or rent, you've probably noticed a difference or will notice one in time. Pat Kiernan sits down with experts and NY1 reporters to unpack the housing crisis and how we can make the market more affordable for everyone who wants to live in New York City.   Join the conversation using #NY1Crosstown. If you like what you hear, share this podcast with your friends and family — it's free for all New Yorkers and beyond. Leave us a rating and review where ever you listen. ABOUT THE SHOW New York City's favorite morning anchor pulls back the curtain on the biggest stories around the five boroughs — the impactful, fascinating, and extraordinary headlines reported each week by Spectrum News NY1. Through intimate conversations with the newsroom's expert journalists, Pat Kiernan illuminates what matters to resident New Yorkers and New Yorkers at heart. HOW TO LISTEN APPLE PODCASTS SPOTIFY STITCHER GOOGLE PLAY RSS

With just days to go until early voting begins, Spectrum News NY1 hosted a lively debate between incumbent Democrat Gov. Kathy Hochul and Republican challenger Lee Zeldin. According to polls, the race has been tightening in recent weeks. How did it get so close? NY1's Zack Fink, Courtney Gross and Juan Manuel Benítez share their takeaways of the debate. The team also examined how campaign strategies, shifting voter priorities and the candidates themselves may have New York on the cusp of electing the first Republican to statewide office in decades.  They also break down the four proposals on the ballot that New Yorkers will decide, including a statewide measure on the environment and three city-based questions on racial equity. We want to hear from you, especially what you think about the governor's race. Leave a message: 212-379-3440 Email: yourstoryny1@charter.com

This week, incumbent Democrat Gov. Kathy Hochul and her Republican challenger, Rep. Lee Zeldin, squared for the first and likely only time in a televised gubernatorial debate hosted by Spectrum News NY1. Moderators Errol Louis and Susan Arbetter of Spectrum News' "Capital Tonight" weighed in on the highlights of the showdown, including the candidates' extremely different policy views in a race that is tighter than many people anticipated. Hochul and Zeldin sparred over issues such as abortion, crime, and pay-to-play allegations. Errol and Susan break it all down and offer their insights. In case you missed it, you can listen to the entire debate immediately after their discussion. Join the conversation, weigh in on Twitter using the hashtag #NY1YouDecide or give us a call at 212-379-3440 and leave a message. Or send an email to YourStoryNY1@charter.com

This week, six of the leading Democratic candidates for New York's 10th Congressional District squared off in a primary debate, co-hosted by Spectrum News NY1 and WNYC-Gothamist. Moderators Errol Louis and Brigid Bergin of WNYC weighed in on the highlights of the showdown, including the moments candidates attacked each other on issues of personal investments and differing policy views. Errol and Brigid shared their thoughts and insights, including what they thought about the candidates' answers to a question about former Mayor Bill de Blasio. And if you missed any part, you can listen to the entire debate immediately after their discussion. Join the conversation, weigh in on Twitter using the hashtag #NY1YouDecide or give us a call at 212-379-3440 and leave a message. Or send an email to YourStoryNY1@charter.com

This week, longtime political titans Rep. Carolyn Maloney and Rep. Jerry Nadler, along with challenger Suraj Patel, squared off in a lively Democratic primary debate, hosted by Spectrum News NY1 and WNYC-Gothamist. Listen to the full showdown, co-moderated by Errol Louis, in which the candidates looked to distinguish themselves ahead of the August 23 primary. The Democrats debated on issues like SCOTUS, climate change and the economy. While Patel focused on the need for new leadership on Capitol Hill, Nadler and Maloney leaned on their lengthy resumes, as they both fight for their political lives. One of the highlights of the evening was a surprising answer to a lightning round question, which caught many off guard. Join the conversation, weigh in on Twitter using the hashtag #NY1YouDecide or give us a call at 212-379-3440 and leave a message. Or send an email to YourStoryNY1@charter.com

The recently signed gun law, S. 2938: Bipartisan Safer Communities Act, contained a surprise dingleberry postponing a regulation designed to save seniors money on their pharmaceutical drugs by prohibiting kickbacks to an industry few have heard of: Pharmacy Benefit Managers (PBMs). This little-known but extremely powerful industry deserves much of the blame for ever rising prescription drugs costs in the United States. In this episode, Jen gives you the scoop on PBMs and how they make their money at the expense of Americans who are most dependent on medications. Please Support Congressional Dish – Quick Links Contribute monthly or a lump sum via PayPal Support Congressional Dish via Patreon (donations per episode) Send Zelle payments to: Donation@congressionaldish.com Send Venmo payments to: @Jennifer-Briney Send Cash App payments to: $CongressionalDish or Donation@congressionaldish.com Use your bank's online bill pay function to mail contributions to: 5753 Hwy 85 North, Number 4576, Crestview, FL 32536. Please make checks payable to Congressional Dish Thank you for supporting truly independent media! View the shownotes on our website at https://congressionaldish.com/cd255-pharmacy-benefit-managers-pbms We're Not Wrong Berlin Meetup Contact Justin at WereNotWrongPod@gmail.com Background Sources Recommended Congressional Dish Episodes CD134: The EpiPen Hearing US Healthcare Landscape Jessi Jezewska Stevens. Apr 23, 2020. “A Brief History of the Great American Healthcare Scam.” Bookforum. Tanza Loudenback. Mar 7, 2019. “The average cost of healthcare in 21 different countries.” Insider. Chuck Grassley and Ron Wyden. 2019. “Insulin: Examining the Factors Driving the Rising Cost of a Century Old Drug [Staff Report].” U.S. Senate Finance Committee. “Health Insurance Coverage of the Total Population.” Kaiser Family Foundation. Sara R. Collins and David C. Radley. Dec 7, 2018. “The Cost of Employer Insurance Is a Growing Burden for Middle-Income Families.” The Commonwealth Fund. PBMs What are PBMs? JC Scott. Jun 30, 2022. “Drug manufacturers are root cause of high drug costs; PBMs drive costs down.” The Hill. Zach Freed. Jun 22, 2022. “The Pharmacy Benefit Mafia: The Secret Health Care Monopolies Jacking Up Drug Prices and Abusing Patients and Pharmacists.” American Economic Liberties Project. Adam J. Fein. Jun 22, 2021. “The Top Pharmacy Benefit Managers of 2020: Vertical Integration Drives Consolidation (rerun).” Drug Channels. “Flash finding: How drug money from sick people really works.” Nov 11, 2021. 46brooklyn. Adam J. Fein. Feb 3, 2019. “Don't Blame Drug Prices on ‘Big Pharma.'” The Wall Street Journal. How PBMs Make Money “DIR Fees.” National Association of Chain Drug Stores. “How PBMs Make Money: PBM Practices & Profits.” RxSafe. True North Political Solutions. Oct 25, 2017. “White Paper: DIR Fees Simply Explained.” Pharmacy Times. ACA “Vertical Integration” Loophole Peter High. Jul 8, 2019. “A View From Inside Cigna's $67 Billion Acquisition Of Express Scripts.” Forbes. Angelica LaVito. Nov 28, 2018. “CVS creates new health-care giant as $69 billion merger with Aetna officially closes.” CNBC. David Dayen. Oct 12, 2018. “Why the Aetna and CVS Merger Is So Dangerous.” The American Prospect. Jeff Byers. April 12, 2018. “Optum a step ahead in vertical integration frenzy.” Healthcare Dive. Graph: Optum opens up wider market for UnitedHealth Group Graph: Optum's pharmacy business contributes the majority of its revenue Susan Morse. May 10, 2017. “Secret weapon: UnitedHealth's Optum business is laying waste to old notions about how payers make money.” Healthcare Finance. Lobbying “Client Profile: Pharmaceutical Care Management Assn.” Open Secrets. The Demise of Independent Pharmacies Christine Blank. Oct 17, 2019. “Independents Prepare to Close Up Shop.” Drug Topics. Paulina Firozi. Aug 23, 2018. “The Health 202: Here's why rural independent pharmacies are closing their doors.” The Washington Post. What Is a Formulary? Ana Gascon Ivey. May 19, 2020. “A Guide to Medication Formularies.” GoodRx. Previous Delays in Rebate Regulation Paige Minemyer. Jan 29, 2021. “In a win for PBMs, Biden administration delays rebate rule.” Fierce Healthcare. Paige Minemyer. Jan 12, 2021. “PCMA sues Trump administration over rebate rule.” Fierce Healthcare. “Incorporating the Effects of the Proposed Rule on Safe Harbors for Pharmaceutical Rebates in CBO's Budget Projections—Supplemental Material for Updated Budget Projections: 2019 to 2029.” May 2019. Congressional Budget Office. The Gun Law Passage Process Office of the Clerk. May 18, 2022. “Roll Call 212 | Bill Number: S. 2938.” U.S. House of Representatives. Tampa Bay Times Editorial Board. May 12, 2022. “Republican lawmakers should be ashamed for failing to honor Justice Joseph Hatchett.” Miami Herald. Annie Karni. Apr 12, 2022. “House G.O.P., Banding Together, Kills Bid to Honor Pioneering Black Judge.” The New York Times. Background on Most Important Provisions Mary Katherine Wildeman. May 26, 2022. “Data show most school shootings carried out by young adults, teens.” CT Insider. Jeffrey Pierre. May 26, 2022. “Experts say we can prevent school shootings. Here's what the research says.” NPR. The Dingleberry Erik Sherman. Jun 30, 2022. “Gun Safety Bill Extends Drug Middlemen Protection From Anti-Kickback Measure.” Forbes. Molly Rutherford. Jun 28, 2022. “Gun legislation provision puts drug supply chain profits over patients.” The Hill. Marty Schladen. Jun 22, 2022. “Deep inside the gun bill: a break for prescription drug middlemen.” Iowa Capital Dispatch. Poland Train Station Taylor Popielarz, Maureen McManus and Justin Tasolides. Mar 25, 2022. “‘The help given is remarkable': Inside the Poland train station that's become a hub for Ukrainian refugees.” Spectrum News NY1. The Law and the Regulation S. 2938: Bipartisan Safer Communities Act Senate Vote: 65-33 (All Nos GOP) House Vote: 234-193 (All Nos GOP) Jen's Highlighted PDF of S. 2938: Bipartisan Safer Communities Act Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees U.S. Health and Human Services Department November 30, 2020 Audio Sources The State of Competition in the Pharmacy Benefits Manager and Pharmacy Marketplaces November 17, 2015 House Committee on the Judiciary Witnesses: Bradley J. Arthur, R.Ph., Owner, Black Rock Pharmacy David Balto, Law Offices of David A. Balto PLLC Amy Bricker, R.Ph. Vice President of Retail Contracting & Strategy, Express Scripts Natalie A. Pons, Senior Vice President and Assistant General Counsel, CVS Health Clips 53:48 Bradley Arthur: The Big Three PBMs control almost 80% of the entire market and these PBMs have the upper hand both in negotiating the contract with the payer, as well as strongly influencing the actual plan design itself. The PBM industry typically states that they can use their economic power to harness enhanced market efficiencies, but for whom? However, the staggering annual revenues that continue to grow each year of the big three suggests that these efficiencies are going directly to their corporations' bottom lines. Small community pharmacies like mine are faced on a daily basis with the impact of the PBMs' disproportionate market power. Community pharmacies routinely must agree to take-it-or-leave-it contracts from the PBMs just to continue to serve our long-standing patients. As if that weren't enough, the PBMs also directly set the reimbursement rates for pharmacies, the very same pharmacies that stand in direct competition of some of these PBM-owned mail-order and specialty pharmacies. Therefore, it comes as no surprise that the PBMs present employer and government payers with carefully tailored suggested plans designs that steer beneficiaries to these PBM-owned entities. Drug Pricing in America: A Prescription for Change, Part I January 29, 2019 Senate Committee on Finance Witnesses: Kathy Sego, Mother of a Child with Insulin-Dependent Diabetes Douglas Holtz-Eakin, Ph.D., President, American Action Forum Mark E. Miller, Ph.D., Vice President of Health Care, Laura and John Arnold Foundation Peter B. Bach, MD, MAPP, Director, Memorial Sloan Kettering Center for Health Policy and Outcomes Clips 1:57:30 Sen. John Cornyn (R - TX): Can anybody on the panel explain to me why we have a general prohibition against kickbacks — they call them rebates — under the Social Security Act, but we nevertheless allow it for prescription drug pricing? What's the sound public policy reason for excluding prescription drug pricing from the anti-kickback rule under federal law? Douglas Holtz-Eakin: I can't explain that and won't pretend to. [laughter] Sen. Cornyn: I thought I was the only one who didn't understand the wisdom of that. Well, it's not a transparent arrangement and it does produce upward pressure on drug prices. And obviously, the negotiations between the PBM and the pharma in terms of what the net cost is, is not transparent, nor is it delivered to the consumer. Is it Dr. Miller? Dr. Bach? Peter Bach: It's delivered to the consumer indirectly through the reduction of the total cost of the benefit, but it is not delivered to the actual consumer using the drug, and that is a disassociation, that is a problem. Because it essentially reverses the structure of insurance. Lowering the total costs are people who use it the least, and raising the costs are people who use it the most, relative to if you allowed the rebate to be used at the point of sale, including all discounts. 1:59:49 Douglas Holtz-Eakin: If we had the negotiation be about the upfront price, so instead of a high list price and a rebate, you just negotiate a lower price, that would be the price that Ms. Sego would pay and insurance companies would look at that and say, okay, she's not paying as much as she used to, we're going to have to make up that money somewhere else and they might raise premiums. That means that people who don't have extreme insulin drug costs would pay a little bit more in a premium every month, and people who have extremely devastating medical conditions and high health care costs would get less costs. That's exactly what insurance is supposed to do. And so the rebate system is more than giving strange incentives on pricing. It's undercutting the purpose of insurance in general. Drug Pricing in America: A Prescription for Change, Part II February 26, 2019 Senate Committee on Finance Witnesses: Richard A. Gonzalez, Chairman and Chief Executive Officer, AbbVie Inc. Pascal Soriot, Executive Director and Chief Executive Officer, AstraZeneca Giovanni Caforio, M.D., Chairman of the Board and Chief Executive Officer, Bristol-Myers Squibb Co. Jennifer Taubert, Executive Vice President, Worldwide Chairman, Janssen Pharmaceuticals, Johnson & Johnson Kenneth C. Frazier, Chairman and Chief Executive Officer, Merck & Co., Inc. Albert Bourla, DVM, Ph.D., Chief Executive Office, Pfizer Olivier Brandicourt, M.D., Former Chief Executive Officer, Sanofi Clips 1:22:03 Albert Bourla: Adverse incentives that favor higher cost biologics are keeping biosimilars from reaching patients. In many cases, insurance companies declined to include lower cost biosimilars in their formularies because they would risk losing the rebates from covering higher cost medicines. I can't think of a more concerning example of a broken system and we need to do something about it. 1:33:35 Sen. Chuck Grassley (R - IA): So many of you have voiced support for the recent rebate rule proposed by the administration. Should the administration finalized this rule, will you commit to lowering your drug prices? Richard Gonzalez [CEO, AbbVie]: Mr. Chairman, we are supportive of the rule. We'd like to see it in its final form, obviously, to make a final decision, but we are supportive of taking the discount to the patient at the point of sale. Sen Grassley: Okay. AstraZeneca? **Pascal Soriot [CEO, AstraZeneca]**The same for us Senator, I would go one step further: if the rebates were removed from the commercial sector as well, we will definitely reduce our list prices. Sen Grassley: Okay. And Bristol? Giovanni Caforio [CEO, Bristol-Myers Squibb]: We have the same positions. Sen Grassley: Okay. Johnson and Johnson? Jennifer Taubert [EVP, J&J]: Yes, we're supportive, and that definitely would be my goal. We would just need to see the final legislation, provided that there aren't additional fees that are added into the system to compensate for the rebates. Sen Grassley: Merck? **Kenneth C. Frazier: I would expect that our prices would go down if we change the system. Again, on the commercial side as well as the Medicare side. Sen Grassley: Okay, Pfizer? Albert Bourla [CEO, Pfizer]: It is a very clear intention that we will not keep a single dollar from these rebates. We will try to move every single penny to the patients and we think if this goes also to the commercial plants that will be even better for more patients. Sen Grassley: Okay. Sanofi? Olivier Brandicourt [Former CEO, Sanofi]: Lowering list price has to be linked to better access and affordability at the counter for the patients. 1:35:20 Sen. Ron Wyden (D - OR): Is it correct that your company, and nobody else, sets the starting price for all drugs sold by Pfizer? Yes or no? Albert Bourla: It is a negotiation with PBMs and they are very powerful. Sen. Wyden: But you still get to set the list price? Albert Bourla: Yes, but we set this price and the rebate limit(?). 1:35:40 Sen. Ron Wyden (D - OR): Is it correct, when a hypothetical patient, let's call her Mrs. Jones, goes to pay for her drug at the pharmacy counter, her coinsurance is based on the price of the drug you set? Albert Bourla: It is correct in many cases. Sen. Wyden: Okay. I just want you all to know that the number one reason consumers are getting hammered, is because these list prices, which you have the last word with respect to where they are, are unaffordable. And the high prices are tied to what the consumer pays at the pharmacy counter. And all this other stuff you talk about, the rebates and the discounts and the coupons, all this other stuff is window dressing, all of that. And the fact is on Part D, 40% of the drugs don't even have a rebate. So I want it understood, particularly because I've asked you, Mr. Borla, I think you and others in the industry are stonewalling on the key issue, which is actually lowering list prices. And reducing those list prices are the easiest way for American consumers to pay less at the pharmacy counter. 2:12:45 Sen. Thomas Carper (D-DE): First is eliminating rebates to PBMs. That's the first one, eliminating rebates to PBMs. The second is value based arrangements. And the third is increasing transparency industry-wide on how you set your prices. 2:13:20 Richard Gonzalez: We clearly support providing the discount at the patient level, eliminating rebates essentially. 2:14:10 Pascal Soriot: If the rebates, as I said earlier, were to be removed from Part D and the commercial sector, we would actually reduce our list prices. 2:15:10 Giovanni Caforio: I would say that not only do we support all three elements that you mentioned, but I do believe those three elements together with the continued effort to develop a generic and biosimilar market would mean significant change, and would clearly alleviate the concerns that patients have today. 2:14:44 Jennifer Taubert: We are very supportive of all three elements that you outlined 2:15:52 Kenneth Frazier: We too support all three. 2:15:55 Albert Bourla: All three elements are transformational for our industry, will disrupt it. However, we do agree that these are the three things that need to be done and also I believe that will have significant meaningful results if we do. 2:16:10 Olivier Brandicourt: We support the three Senator, but we want to keep in mind at the end of the chain the patient has to benefit, so if rebates are removed it has to be to the benefit of patients. Sen. Thomas Carper (D-DE): Good, thanks. 2:18:10 Albert Bourla: 50% of the American people are in commercial plans and these rebate rules apply to Medicare. If the rules apply to all, definitely the list price will go down. 2:18:30 Albert Bourla: The list price is not irrelevant, it's very relevant for a lot of people because they have to pay list price during the deductible period. However if the rebate rule is applied, then they become irrelevant because the patients will not be paying the list price at the purchase point. 2:19:10 Sen. John Thune (R-SD): How would manufacturers respond if the rebate rule were finalized for government programs? I mean, what does that what does that mean for the commercial market? Albert Bourla: Senator, as I said before, all these proposals that they're discussing, [undistinguishable], eliminating the rebate rule, are transformational and will disrupt the way we do business. I don't know exactly how the system will evolve, and I really don't favor a bifurcated system. I would like to have a transparent single system across both parts. So we need to see how the whole thing will evolve. 2:25:26 Johnny Isakson (R-GA): Who sets the discount and who sets the rebate? 2:26:20 Richard Gonzalez: We negotiate with payers, so managed care and PBMs— Sen. Johnny Isakson (R-GA): You're a supplier though, so you have to go negotiate with the PBMs and those people, is that right? Richard Gonzalez: Correct, and they negotiate aggressively. Sen. Isakson: Is that pretty much true with everybody, that they're the major component between the end retail consumer price and the origin of the product? Richard Gonzalez: Yes, Senator. Sen. Isakson: Well, that seems like that's someplace we ought to focus, because that's where the distorted numbers come in. Johnson & Johnson, Janssen, in your testimony, you talked about your average list price of 8.1%, up, but an average net price change of only 4.6%. So while your gross went up 8.6, your net went down 4.6 In the same pricing period. How does that happen? If you're setting the price, how does it not go up on the bottom? Jennifer Taubert: Yeah, and in fact, in 2018, our net price actually declined 8.6%, so even more than that. The intermediaries in the system are very, very effective negotiators— Sen. Isakson: Tell me who the intermediaries are. Jennifer Taubert: Those would be the PBMs and the insurers. Sen. Isakson: …and the insurance companies? Jennifer Taubert: Right, and they set the formularies for patients. Sen. Isakson: And they're not the same. They're two different people? Jennifer Taubert: Yes, correct. 2:40:45 James Lankford (R-OK): All of you have mentioned the rebate issue has been a problem and that insurance companies and PBMs are very effective negotiators. Part of the challenge of this is, health insurance companies pay their PBM based on the quality of their negotiation skills, cutting a price off the list price. And so if a list price is higher and a rebate is higher, that also gives preference to them. So the difficulty is, as you raise list price, and the rebate gets larger, the insurance company gives that preference, making it harder for biosimilars. Am I tracking this correctly? 2:43:00 Albert Bourla: Here in the US, the penetration of biosimilars is much lower than in other places, but it is disproportional to different parts of the US healthcare system. For example, in open systems, systems where the decision maker it is a PBM, the one biosimilar we have has a market share of 5% in the US. In closed systems, in systems like Kaiser, for example, integrated healthcare systems where the one who decides has the whole cost of the healthcare system in its interest, we have 73%. 5% and 73% for the same product. I agree with what Mr. Fraser said that we need to create incentives, but I would add also that we need to break this rebate trap that creates significant disincentives for providers, and the healthcare system, and insurance companies. 3:19:25 Kenneth Frazier: If you went back a few years ago, when we negotiated to get our drugs on formulary, our goal was to have the lowest copay by patients. Today the goal is to pay into the supply chain the biggest rebate, and so that actually puts the patient at a disadvantage since they're the only ones that are paying a portion of the list price. The list price is actually working against the patient. 3:19:50 Sen. Steve Daines (R-MT): Why do we have a system today? Where you all are setting, I'll just say very, very high list prices, which is the starting point for negotiation. Why? Olivier Brandicourt: Senator, we're trying to get formulary position. With those list prices. High list price, high rebates. It's a preferred position. Unfortunately the preferred position doesn't automatically ensure affordability at the end. Kenneth C. Frazier: Senator, If you bring a product to the market with a low list price in this system, you get punished financially and you get no uptake because everyone in the supply chain makes money as a result of a higher list price. Drug Pricing in America: A Prescription for Change, Part III April 9, 2019 Senate Committee on Finance Witnesses: Steve Miller, MD, Former Executive Vice President and Chief Clinical Officer, Cigna Corporation Derica Rice, Former Executive Vice President and President, CVS Health and CVS Caremark William Fleming, Pharm.D., Segment President, Healthcare Services, Humana Inc. John Prince, Chief Executive Officer, OptumRx Mike Kolar, JD, Interim President & CEO, Senior Vice President and General Counsel, Prime Therapeutics LLC Clips Sen. Ron Wyden (D - OR): Pharmaceutical Benefit Managers first showed up decades ago, back when prescription drugs were being utilized more extensively. The PBMs told the insurance companies, “we're the ones who know drug pricing, we will handle the negotiations for you.” But there is little evidence that the pharmaceutical benefit managers have actually held down the prices in a meaningful way. In fact, most of the evidence shows just the opposite. Pharmaceutical Benefit Managers actually make more money when they pick a higher price drug over a lower price drug. Colleagues, let's remember that all the way through this discussion, benefit managers make more money when they pick a higher price drug over a lower price drug. The logic on this isn't exactly complicated, graduate-level economics. PBM profits are based on taking their slice of the prescription-drug pie. More expensive drugs means there's a bigger pie. When there's a bigger pie, [there are] bigger slices for the pharmaceutical benefit managers. 50:24 Mike Kolar: Rebates and the role they play have been key areas of focus in the drug cost debate. In our view, rebates are a powerful tool to offset high prices, which are set by pharmaceutical companies, and pharmaceutical companies alone. The fact that rebates are not offered on many of the highest cost drugs, and that studies show no correlation between prices and rebates underscore that rebates are a key to mitigating rather than causing high drug prices. We pass rebates through fully to our plans, and we believe our plans should be able to choose how to apply these rebates in ways that best serve their members and market needs by balancing premiums and cost sharing. 56:05 Sen. Chuck Grassley (R-IA): I'd like to talk about consolidation, including the recent integration of PBMs with insurance companies. Last year I wrote to the Justice Department on the issues, it reported that the three largest PBMs who are before us today now covers 71% of Medicaid, Medicare Part D enrollees and 86% of standalone Drug Plan enrollees. 57:45 Derica Rice: This is a highly competitive space. In addition to the three that you've pointed out here, CMS has noted there are over 60 PBMs across the US. Therefore, the competition, there's many options for the employers that are out there, government entities, as well as unions to choose from given their specific needs. 1:10:35 Sen. Debbie Stabenow (D-MI): So when we look at Express Scripts has 100 million Americans covered, CVS 90 million, OptumRx 65 million, Prime Therapeutics 27 million, Humana 21 million, and yet Americans still pay the highest prices in the world. Even though you are negotiating for millions of people. The VA has its own pharmacy benefit manager service, they negotiate for 9 million veterans, and they pay, on average, 40% less for the same drugs that the rest of the healthcare system pays for. Despite greater volume, you are unable to secure these kinds of low prices. With all due respect, you guys are pretty bad negotiators. Given the fact that the VA can get 40% less. And so I'd like to know from each of you why that's the case. Dr. Miller? Steve Miller [Former EVP and Chief Clinical Officer, Cigna Corporation]: Yes. Part of the equation is giving patients choice. At the VA, they actually limit their formulary more than any of us at this table do. So oftentimes, they'll have one beta blocker, one ace inhibitor. And so if it's going to get to that level of choice, then we could get better prices also. Sen. Stabenow: Let me jump in, in the interest of time. I know you create nationwide drug formularies, you have pre-authorization, you give preferred status to certain medications. So you don't use any of those tools that the VA is using? Because you do. Steve Miller: We definitely use those tools, but we also give people choice. It's crucial for both physicians and patients to have the choice of the products they want to be able to access. Many of our plans want us to have broad formularies and when you have more products, it means you move less market share. Sen. Stabenow: So basically you're saying a 40% premium gives them more choice. 1:24:30 Sherrod Brown (D-OH): If the administration's rebate rule were finalized as proposed, would you in some way be required to change the way you do business? Mike Kolar: Yes, Senator we would. John Prince: Yes. William Fleming: Yes. Derica Rice: Yes. Steve Miller: Yes. Sen. Brown: Thank you. 1:25:05 Sherrod Brown (D-OH): What percentage of prescriptions that you fill across Part D actually receive a rebate? Roughly what percentage? Mike Kolar: So Senator, approximately 8% of the prescriptions that we cover in Part D are associated with a rebate. Sen. Brown: Okay, Mr. Prince? John Prince: Senator, I don't know the exact number, I know our overall business is about 7%. Sen. Brown: Okay, thank you. William Fleming: About 7-8%. Derica Rice: Senator, I do not know the exact number but we pass through 100% of all rebates and discounts. Sen. Brown: [Grunt] Steve Miller: 90% of the prescriptions will be generic. Of the 10% that are branded, about two-thirds have rebates. So it's about seven-- Sen. Brown: 7-8% like the others. Okay. To recap, PBMs do not set drug prices. Forcing you to change the way you do business -- as the administration's rule would — will not change that fact. And while the rule might impact a small percentage of drugs and Part D that receive a rebate, it does nothing to lower costs, as your answer suggests, for the other 90% of prescriptions you fill. Most importantly, absolutely nothing in the proposed rule would require Secretary Azar's former employer or any other pharma company to lower the price of insulin or any other drug. It's important to establish that, so thank you for that. 1:41:40 Catherine Cortez Masto (D-NV): Let me ask you, Dr. Fleming, in your testimony, you say Humana's analysis of the rebate rule -- and we're talking about the administration's rebate rule now — found that approximately 17% of beneficiaries will see savings at the pharmacy counter as a result of this rule. Can you tell me a little bit more about who these people are? And what kind of conditions do they have? William Fleming: Senator, there will be a number of members who are taking brand drugs for which we get rebates and so it could vary all the way from the common chronic conditions, things like diabetes or hypertension or high cholesterol, all the way over to occasionally, not usually, but occasionally on the specialty drug side. When you think of some medications like treatments for rheumatoid arthritis, multiple sclerosis, places where there's competition. Cover Art Design by Only Child Imaginations Music Presented in This Episode Intro & Exit: Tired of Being Lied To by David Ippolito (found on Music Alley by mevio)

Welcome to Episode 88 of Pelo Buddy TV, an unofficial Peloton podcast & Peloton news show. This week we cover the following topics: Sam Yo & Erik Jager will be teaching power zone classes. Peloton briefly tested a new “Personalized” sort order of the on demand class library. The Peloton Guide got several updates this week, including support for using an Apple Watch as a heart rate monitor. The Apple Watch was updated and can now show the name & time remaining of the current segment of the class you are in. We look at how there has been fewer 45 minute rides recently than there were in the early days of Peloton. Peloton's new CEO is “hopeful” about the return of the Tread+ The Bike+ is no longer available through Peloton's rental program online. Daniel McKenna will teach his first class since his injury on July 14th. There are a number of special classes (& a new badge) in a partnership with the Wimbledon tennis tournament. There are no live classes from July 3-5, and there are some “Fourth of July” classes. Peloton had a special “Rush” artist series on Friday in celebration of Canada Day. Several Peloton instructors are attending Essence Fest in New Orleans with some member meetups. Following our update last week, the studio booking website is now password protected. The Peloton stock price hit a new all-time low this week, dropping below $9. Peloton is having an apparel sale over the 4th of July Weekend Jess King sat down with Spectrum News NY1 to talk about pride, her engagement & pregnancy, the Peloton community, and more. Jess King also went into detail with PopSugar about her pregnancy. Dr. Chelsea Jackson Roberts was featured in Ebony in an article that discussed how she “Modernizes the Ancient Practice With a Hip Hop Soundtrack.” Christine D'Ercole will speak on a panel at BroadwayCon. Andy Speer got a new puppy. John & Amanda share community members', and their own, class picks of the week. You can find links to full articles on each of these topics from the episode page here: https://www.pelobuddy.com/pelo-buddy-tv-episode-88/ The show is also available via YouTube: https://www.youtube.com/c/PeloBuddy This episode is hosted by Amanda Segal (#Seglo3) and John Prewitt (#Kenny_Bania).

Elizabeth Kim, reporter who covers mayoral power for the People and Power team at Gothamist and WNYC, and Juan Manuel Benitez, reporter at Spectrum News NY1 and host of PuraPolítica, talk about the latest city news, including the Adams' Administration's work to clear encampments of unhoused people and more.

On this Tuesday edition of Bernie & Sid in the Morning, Sid picks a twitter fight with Spectrum News NY1 anchor Errol Louis for not challenging Andrea Stewart-Cousins on her ridiculous claim that bail reform is not the catalyst for New York's spike in crime. In other news of the day, Pentagon Press Secretary John Kirby says we could see Vladimir Putin and Russia move on Ukraine with "little to no warning," National Security Advisor Jake Sullivan says if Putin does so the United States will be prepared to respond, the Durham report revelations regarding Hillary Clinton's 2016 campaign spying on President Trump and the White House picks up more speed, Canadian Prime Minister Justin Trudeau addresses the possibility of calling in the military to break up the protesting truckers, and Whoopi Goldberg returns to "The View." Learn more about your ad choices. Visit megaphone.fm/adchoices

Frank DiLella is one of Broadway's most recognizable faces. As the Emmy Award winning host of ON STAGE, a weekly theater program on Spectrum News NY1, Frank has served as a correspondent on- and off-Broadway and around the world, and hosts his own podcast “Show and Tell with Frank DiLella” on iHeart Radio. A strong advocate for arts education, join Frank as he recounts some of his favorite backstage stories and the joys of doing good—this time from the other side of the mic! Learn more about about the worthy causes discussed in this episodes and how you can donate and/or help: The Roger Rees Awards The Clive & Valerie Barnes Foundation The Actors Fund Jimmy Awards Connect with Frank: Website: FrankDiLella.com  Facebook: @FrankDiLella Twitter: @fdilella Instagram: @fdilella On Stage Show & Tell with Frank DiLella podcast NY1 Connect with The Broadway Gives Back Podcast: Facebook: @broadwaygivesbackpodcast Instagram: @broadwaygivesbackpodcast Twitter: @broadwaygives Hosted & Executive Produced by Jan Svendsen and co-produced & edited by Jim Lochner. A proud member of the Broadway Podcast Network. Special thanks to Dori Berinstein, Alan Seales, and Kimberlee Garris from BPN; Julian Hills from The Bulldog Agency; and Eric Becker from Broderick Street Music. Learn more about your ad choices. Visit megaphone.fm/adchoices

After being shut down for more than 15 months, the lights of Broadway are coming back on! To share the excitement, our hosts meet with Frank DiLella, Emmy Award-winning host of “On Stage” on Spectrum News NY1, the news channel's weekly half-hour theater program. Together they discuss the most anticipated shows of the season, the future of Broadway, and if things will ever be the same again. The episode inaugurates the second season of The Accutron Show, now also available on video. Quiet now... it's our opening night!Episode Highlights:16:43 Everyone was texting me saying Broadway was shutting down for 2 weeks, or 4 weeks. Then one of my co-anchors and dear friend of mine told me, "Frankie baby, this is going to be for a long time!" 26:11 There is no formula for a Broadway show to be a hit. Word of mouth is the strongest thing for a musical to be successful. 39:45 In order for Broadway to succeed right now, new yorkers really need to show up. This is something that is part of our heritage. I have missed it, I have been craving it, I intend to support it but without our tourists, we need to be there and make these shows work. Learn more about the Accutron watch here, and follow @AccutronWatch:InstagramTwitterFacebookSubscribe to this podcast on Apple Podcasts and Spotify to hear new episodes as soon as they're released.Follow our hosts on social media:Bill McCuddy: Facebook  / TwitterDavid Graver: Instagram

Errol Louis, political anchor of Spectrum News NY1, host of Inside City Hall, Daily News columnist and host of the podcast "You Decide" joins to discuss the latest on the ranked-choice voting tally and city budget news.

Juan Manuel Benitez, host of PuraPolítica and reporter at Spectrum News NY1, talks about how Spanish-language media are covering the mayoral campaign, and what Spanish-speaking New Yorkers are telling him and other reporters what they're thinking about the election.